A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK),
and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of
GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following
single and multiple ascending doses.